IRLAB Therapeutics
31.12.2021 10:51:35 CET | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.
According to IRLAB's articles of association, the board shall consist of at least three (3) and at most (10) members. When Nicklasson leaves the board, it will consist of five (5) members, and will thus continue to fulfill this requirement up to the next annual general meeting in May 2022, when a new board shall be chosen.
"On behalf of the board and shareholders I would like to extend a hearty thank-you to Martin for his valuable input to board activities this past year," says Gunnar Olsson, IRLAB's chairman of the board. "2021 has been a transformative period in IRLAB's development. Our successful license deal with mesdopetam and the regulatory approvals for the start of the Phase IIb study with pirepemat have given us a completely new basis for achieving IRLAB's long-term goals."
For more information
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders of the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
Attachments
Board member leaves IRLAB for another assignment
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/680352/Board-Member-Leaves-IRLAB-for-Another-Assignment
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
FINOS Launches AI Fund to Amplify the Collective Voice of the Financial Services Industry and Accelerate Responsible Agentic AI Adoption23.6.2026 10:00:00 CEST | Press release
Founding premier members DTCC, Morgan Stanley, RBC and NatWest join forces to collectively invest in open source AI, to advance common governance, controls, specifications, reference implementations, and intra and inter-firm agentic workflows for financial services, helping the industry shape safer AI adoption, reduce fragmentation, and accelerate real-world implementation. LONDON, UK / ACCESS Newswire / June 23, 2026 / The Fintech Open Source Foundation (FINOS) today announced the establishment of the FINOS AI Fund and the formation of its dedicated Governing Board. Anchored by Founding Premier Members The Depository Trust & Clearing Corporation (DTCC), Morgan Stanley, Royal Bank of Canada (RBC), and NatWest, the Fund is designed to help the industry collectively shape the governance, standards, and implementation foundations needed for responsible agentic AI adoption in regulated financial services. The Case for an Industry-Led AI Approach in Financial Services General AI technology
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds23.6.2026 06:45:00 CEST | Press release
"What CTOs Think 2026: Scaling the agentic enterprise with confidence" reveals for the first time, innovation, not efficiency, as the primary driver of digital investment, signaling a move from cost-focused optimization toward growth. ZURICH, SWITZERLAND / ACCESS Newswire / June 23, 2026 / New research released today by Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, shows that CTO confidence in scaling AI is declining, falling to 48% in 2026 from 82% in 2024 - even as AI adoption accelerates and enterprises face growing pressure to turn ambition into execution at scale. Image: What CTOs Think 2026: Scaling the agentic enterprise with confidence. Source: Akkodis The third edition of Akkodis' What CTOs Think report, What CTOs Think 2026: Scaling the agentic enterprise with confidence, features insights from 500 Chief Technology Officers (CTOs) as part of the Adecco Group's Business Leaders 2026 research of 2,000 C-suite executives, The human prem
LiberNovo Prime Sale Fully Launches June 23: Full Chair Lineup and Accessories, Up to 49% Off23.6.2026 04:00:00 CEST | Press release
The limited Omni Premium Bundle headlines a flash sale across the EU and UK, stacked with tiered gifts, a prize wheel, and triple loyalty points, from June 23 through July 11. HONG KONG, HK / ACCESS Newswire / June 22, 2026 / LiberNovo today opened one of its biggest sales of the year. From June 23 through July 11, the entire collection goes on sale across the EU and UK with savings of up to 49% off, and the headline deal is the Omni Premium Bundle: a limited flash-sale price on the original Omni, starting from €939 ( £869) up to 49% off, the chair that started it all, available only while clearance stock lasts. Accessories and the rest of the range join at Prime Sale pricing too, making it the best time of the year to build your complete setup. Every LiberNovo chair is built on the world's first dynamic ergonomic design. A flexible backrest bends and moves with you as you shift, lean, and change position, so your support follows your body instead of holding you in one pose. A powered
Leggett Dynamics Launches Mid-Class Massage System & Makes Luxury Comfort Accessible on High-Volume Programs22.6.2026 13:00:00 CEST | Press release
DETROIT, MI / ACCESS Newswire / June 22, 2026 / Leggett Dynamics today launched its Mid-Class Massage System (MCM), a breakthrough non-electronic innovation that makes premium massage more accessible beyond the luxury vehicle segment. Now in production with a global OEM, MCM was also shortlisted for the 2026 Auto Tech Partnership Award for industry-leading innovation and collaboration. Breakthrough by Design MCM creates a distinctive massage experience with a compact 30 x 35 mm module that uses the Coandă effect, an air jet's natural tendency to follow a curved surface. With no electronics or moving parts, it reduces complexity and cost, making a premium experience accessible to more vehicle segments and consumers. Balancing Innovation, Speed and Cost "Automakers must balance innovation, speed and cost while consumers expect more personalized, affordable, premium experiences," said Julien Rea, VP of Global Innovation & Engineering at Leggett Dynamics. "Leggett Dynamics' Mid-Class Massa
EcoModular Advances EIC STEP Scale Up Application to Support European Manufacturing Expansion22.6.2026 09:55:00 CEST | Press release
AI-native robotics platform engages European innovation-funding specialist Catalyze to prepare its submission to the European Innovation Council's STEP Scale-Up programme, with its EU Manufacturing Hub as the anchor of a planned European scale-up DUBLIN, IE / ACCESS Newswire / June 22, 2026 / EcoModular, the AI-native robotics platform for volumetric manufacturing operated by Ascotway Limited and advancing a Nasdaq Capital Market direct listing, today announced that it has engaged Catalyze B.V., a leading European innovation-funding consultancy, to prepare and submit an application to the European Innovation Council (EIC) STEP Scale-Up programme. The application is being prepared for the programme's evaluation batch dated 9 September 2026. The EIC STEP Scale-Up programme forms part of the European Union's Strategic Technologies for Europe Platform (STEP) and is administered by the European Innovation Council. It is designed to provide investment support to European companies scaling st
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom